Efficacy of pharmacological interventions for ADHD: protocol for an updated systematic review and dose-response network meta-analysis.
Options
BORIS DOI
Publisher DOI
PubMed ID
39396049
Description
Background
Attention-deficit/hyperactivity disorder (ADHD) affects approximately 5% of children globally, with symptoms often persisting into adulthood. While pharmacological interventions are commonly employed for management, understanding the optimal dosing for efficacy and tolerability remains crucial. This study aims to conduct a dose-response network meta-analysis to estimate the efficacy of pharmacological treatments across different doses, aiming to inform clinical decision-making and improve treatment outcomes.Methods
This updated systematic review will include randomized controlled trials evaluating ADHD medication efficacy in children, adolescents, and adults. An updated search from a 2018 NMA will be conducted across multiple electronic databases with no language restrictions, using specific eligibility criteria focused on randomized controlled trials. The primary outcome will assess the severity of ADHD core symptoms, while secondary outcomes will consider treatment tolerability. A dose-response Bayesian hierarchical model will be used to estimate dose-response curves for each medication, identifying optimal dosing strategies.Discussion
With this dose-response network meta-analysis, we aim to better understand the dose-response relationship of pharmacological treatment in ADHD, which could help clinician to the identification of optimal doses.Systematic Review Registration
OSF https://doi.org/10.17605/OSF.IO/3MY4A .
Attention-deficit/hyperactivity disorder (ADHD) affects approximately 5% of children globally, with symptoms often persisting into adulthood. While pharmacological interventions are commonly employed for management, understanding the optimal dosing for efficacy and tolerability remains crucial. This study aims to conduct a dose-response network meta-analysis to estimate the efficacy of pharmacological treatments across different doses, aiming to inform clinical decision-making and improve treatment outcomes.Methods
This updated systematic review will include randomized controlled trials evaluating ADHD medication efficacy in children, adolescents, and adults. An updated search from a 2018 NMA will be conducted across multiple electronic databases with no language restrictions, using specific eligibility criteria focused on randomized controlled trials. The primary outcome will assess the severity of ADHD core symptoms, while secondary outcomes will consider treatment tolerability. A dose-response Bayesian hierarchical model will be used to estimate dose-response curves for each medication, identifying optimal dosing strategies.Discussion
With this dose-response network meta-analysis, we aim to better understand the dose-response relationship of pharmacological treatment in ADHD, which could help clinician to the identification of optimal doses.Systematic Review Registration
OSF https://doi.org/10.17605/OSF.IO/3MY4A .
Date of Publication
2024-10-12
Publication Type
Article
Subject(s)
600 - Technology::610 - Medicine & health
300 - Social sciences, sociology & anthropology::360 - Social problems & social services
Keyword(s)
Attention deficit/hyperactivity disorder
•
Dose-responsenetwork meta-analysis
•
Pharmacotherapy
Language(s)
en
Contributor(s)
Nourredine, Mikail | |
Jurek, Lucie | |
Cipriani, Andrea | |
Subtil, Fabien | |
Cortese, Samuele |
Additional Credits
Institut für Sozial- und Präventivmedizin (ISPM) - Evidence Synthesis Methods
Institute of General Practice and Primary Care (BIHAM)
Series
Systematic Reviews
Publisher
BioMed Central
ISSN
2046-4053
Access(Rights)
open.access